Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar 9:11:60-62.
doi: 10.1016/j.jdcr.2021.03.007. eCollection 2021 May.

Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis

Chia-Jui Su  1 , Han-Chi Tseng  1
Affiliations
Case Reports

Treatment efficacy of dupilumab in a hyper-immunoglobulin E syndrome patient with severe atopic dermatitis

Chia-Jui Su et al. JAAD Case Rep. .
No abstract available

Keywords: EASI, eczema area and severity index; HIES, hyper-immunoglobulin E syndrome; IU, international units; IgE, immunoglobulin E; atopic dermatitis; dupilumab; hyper-immunoglobulin E syndrome.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Four weeks after the beginning of treatment, diffuse xerosis, erythematous papules, and plaques over trunk and forearm were observed.
Fig 2
Fig 2
Ten months after the beginning of treatment, resolution of hyperpigmentation, erythematous papules, and plaques was observed.
See this image and copyright information in PMC

References

    1. Yong P.F., Freeman A.F., Engelhardt K.R., Holland S., Puck J.M., Grimbacher B. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14(6):228. - PMC - PubMed
    1. Joshi A.Y., Iyer V.N., Hagan J.B., St Sauver J.L., Boyce T.G. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22. - PMC - PubMed
    1. Freeman A.F., Holland S.M. The hyper-IgE syndromes. Immunol Allergy Clin North Am. 2008;28(2):277–291. viii. - PMC - PubMed
    1. Simpson E.L., Bieber T., Guttman-Yassky E. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. - PubMed
    1. Simpson E.L., Paller A.S., Siegfried E.C. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56. - PMC - PubMed

Publication types

LinkOut - more resources